EraGen, Applied BioCode partner to commercialize molecular diagnostics

Applied BioCode, Inc. and EraGen Biosciences Inc. today announced that they have entered into a strategic partnership and license agreement. The agreement provides EraGen with access to Applied BioCode's Barcoded Magnetic Bead technology and the CE-marked BioCode-1000 system. The technology provides a robust and reliable solution for development and clinical laboratory use of multiplexed infectious disease and genetic tests.

"We are very pleased to partner with EraGen in such an important and valuable segment of the molecular diagnostics market. The combination of EraGen's patented chemistry with our Barcoded Magnetic Beads and BioCode-1000 system will provide a powerful testing platform for clinical laboratories," said Winston Ho, Ph.D., president of Applied BioCode. "Our strategic partnership and license agreement with EraGen in an important part of our efforts to commercialize the Barcoded Magnetic Bead product globally."

"The versatility of EraGen's DNA and RNA detection chemistry is a cornerstone of our efforts to continually better serve our clinical laboratory customers," said Irene Hrusovsky, M.D., chairman and chief executive of EraGen. "We look forward to commercializing molecular diagnostics that address not only customers needing real-time molecular testing, but also those in the growing segment that need highly-multiplexed in vitro diagnostics. Our relationship with Applied BioCode will help us reach those goals."